Literature DB >> 20425407

Vaccination strategies in follicular lymphoma.

Shibichakravarthy Kannan1, Sattva S Neelapu.   

Abstract

Follicular lymphoma is one of the most immune-responsive cancers. The clonal tumor immunoglobulin expressed on the surface of malignant B cells, termed idiotype, has been used as a tumor-specific antigen in therapeutic vaccination strategies for follicular lymphoma and other B-cell malignancies. A number of phase 1 and phase 2 clinical trials have established the safety and immunogenicity of idiotype vaccine in follicular lymphoma. Three randomized, double-blind, controlled phase 3 clinical trials have recently been completed to definitively evaluate the clinical benefit of idiotype vaccine in follicular lymphoma. This review focuses on the results of these idiotype vaccine trials and discusses potential strategies to enhance the efficacy of vaccines in the future.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20425407     DOI： 10.1007/s11899-009-0025-2

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  34 in total

1.  Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity.

Authors:  A Biragyn; K Tani; M C Grimm; S Weeks; L W Kwak
Journal:  Nat Biotechnol       Date:  1999-03       Impact factor: 54.908

2.  Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.

Authors:  Zhi-Zhang Yang; Anne J Novak; Mary J Stenson; Thomas E Witzig; Stephen M Ansell
Journal:  Blood       Date:  2006-01-10       Impact factor: 22.113

Review 3.  Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.

Authors:  Hyun Jun Park; Sattva S Neelapu
Journal:  Br J Haematol       Date:  2008-04-13       Impact factor: 6.998

4.  DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma.

Authors:  C A King; M B Spellerberg; D Zhu; J Rice; S S Sahota; A R Thompsett; T J Hamblin; J Radl; F K Stevenson
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

Review 5.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

6.  Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target.

Authors:  G T Stevenson; E V Elliott; F K Stevenson
Journal:  Fed Proc       Date:  1977-08

7.  A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones.

Authors:  Seung-Tae Lee; Shujuan Liu; Laszlo Radvanyi; Pariya Sukhumalchandra; Jeffrey J Molldrem; Eric D Wieder; Patrick Hwu; Yong-Jun Liu; Larry W Kwak; Gregory Lizée; Sattva S Neelapu
Journal:  J Immunol Methods       Date:  2007-10-09       Impact factor: 2.303

8.  Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.

Authors:  L W Kwak; M J Campbell; D K Czerwinski; S Hart; R A Miller; R Levy
Journal:  N Engl J Med       Date:  1992-10-22       Impact factor: 91.245

9.  Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein.

Authors:  M S Kaminski; K Kitamura; D G Maloney; R Levy
Journal:  J Immunol       Date:  1987-02-15       Impact factor: 5.422

10.  Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.

Authors:  Arnold Freedman; Sattva S Neelapu; Craig Nichols; Michael J Robertson; Benjamin Djulbegovic; Jane N Winter; John F Bender; Daniel P Gold; Richard G Ghalie; Morgan E Stewart; Vanessa Esquibel; Paul Hamlin
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544
View more
  5 in total

1.  Current status of immunotherapy for the treatment of lung cancer.

Authors:  Sanjay Murala; Vamsi Alli; Daniel Kreisel; Andrew E Gelman; Alexander S Krupnick
Journal:  J Thorac Dis       Date:  2010-12       Impact factor: 2.895

2.  Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders.

Authors:  Jooeun Bae; Yu-Tzu Tai; Kenneth C Anderson; Nikhil C Munshi
Journal:  Br J Haematol       Date:  2011-09-09       Impact factor: 6.998

3.  Getting personal with neoantigen-based therapeutic cancer vaccines.

Authors:  Nir Hacohen; Edward F Fritsch; Todd A Carter; Eric S Lander; Catherine J Wu
Journal:  Cancer Immunol Res       Date:  2013-04-07       Impact factor: 11.151

4.  Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.

Authors:  Alejandro López-Requena; Oscar R Burrone; Michela Cesco-Gaspere
Journal:  Front Oncol       Date:  2012-11-09       Impact factor: 6.244

5.  Therapy of newly diagnosed follicular lymphoma.

Authors:  Jason R Westin; Sattva S Neelapu
Journal:  Front Oncol       Date:  2012-12-11       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.